# 1stBiome receives Innobooster grant to advance precision biotics for metabolic health and longevity

**The project will optimize 1stBiome's lead microbial strains, establish bench-scale fermentation and develop commercially relevant formulations in preparation for safety studies and human trials.**

**Copenhagen, Denmark – 7th August, 2026** - 1stBiome, a gut-focused biotechnology company developing engineered microbes designed to support metabolic health and longevity, has received an Innobooster grant to accelerate the development of its lead microbial strains and advance its precision biotics platform.

The company's initial development program focuses on low-grade inflammation, a biological condition resulting from unhealthy live style and aging, and associated with metabolic dysfunction, obesity, prediabetes and age-related decline.

"Low-grade inflammation sits at the intersection of gut health, metabolic health and longevity, but most existing consumer products address it only indirectly," said **Ejner Bech Jensen, Co-founder & CEO** at 1stBiome. "Our ambition is to develop beneficial microbes with defined functions and mechanisms of action that support a healthy inflammatory response in the gut. The Innobooster grant allows us to translate our scientific platform into robust strains and formulations that can ultimately be evaluated in humans."

**Advancing from strain development toward commercial readiness**

During the Innobooster project, 1stBiome will optimize its lead strains, scale production to a 1-litre bench fermenter and develop formulations suitable for further commercial development.

The project will focus on improving strain performance, robustness, production efficiency, and formulation characteristics. By the end of the project, 1stBiome expects to have commercially relevant lead strains ready to progress into larger-scale manufacturing, safety studies and human clinical evaluation.

The development program represents an important step in establishing a repeatable pathway from microbial engineering and strain selection to scalable production and product development.

**Best of both worlds**

1stBiome believes precision biotics for metabolic health can occupy a distinct position between conventional probiotics and pharmaceutical microbiome therapeutics.

Conventional probiotics are generally marketed around broad benefits such as digestive or immune health. Pharmaceutical live biotherapeutics, by contrast, focus on the treatment of a specific disease and require extensive clinical development and pharmaceutical regulatory approval.

Precision biotics are intended to combine elements of both approaches to provide products with defined and testable microbial functions, scientific and mechanistic validation, oral delivery, scalable fermentation and a commercialization pathway potentially compatible with food or dietary-supplement regulations.

The company's initial commercial focus is the US metabolic-health and longevity market, which represents a +$1 billion opportunity.

Growing consumer demand for science-backed wellness products, biomarker-driven health optimization and solutions supporting metabolic health has created a favorable environment for products capable of demonstrating measurable biological effects.

**About 1stBiome**

1stBiome is a gut-focused biotechnology company engineering beneficial microbes to reduce low-grade inflammation and support metabolic health and healthy longevity.

1stBiome is supported by BioInnovation Institute (BII)

**Media contact**

**Ejner Bech Jensen**
**Co-founder & CEO**
1stBiome
ejner@1stbiome.com